Expression of enhancer of zeste homolog 2 (EZH2) has been implicated in cancer pathology, but research on its mechanistic activity is limited. The present study sought to assess the levels expression of EZH2 in patients with endometrial carcinoma (EC) and to explore the effects of EZH2 downregulation on the biological behavior of endometrial carcinoma RL-952 cells. Samples were obtained from a ...

Postmenopausal bleeding (PMB) is a common clinical problem. Patients with PMB have 10%-15% chance of having endometrial carcinoma and therefore the diagnostic workup is aimed at excluding malignancy. Patient characteristics can alter the probability of having endometrial carcinoma in patients with PMB; in certain groups of patients the incidence has been reported to be as high as 29%. Transvagi...

Endometrial adenocarcinoma is staged surgically, and advanced endometrial carcinoma is considered to be FIGO stage III and IV. The Gynecologic Oncology Group (GOG) has come a long way in developing new strategies in the management of advanced endometrial carcinoma. Combining surgery, radiation, and chemotherapy, the 5-year survival has improved to between 40-60% in newly diagnosed advanced endo...

BACKGROUND It is well known that peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) plays an important role in tissue energy metabolism. However, the roles of PGC-1α in malignant endometrial cancer remain unknown. METHODS Forty cases of endometrial carcinoma, 15 cases with proliferative endometrial tissues, and 21 cases with normal endometrial tissues were collected...

Breast cancer constitutes 54.8 percent of deaths from malignancies in female genital tract in Malaysia, 19951• It is also the second most common death (19.4%) from malignancies in females in Malaysia. The use of adjuvant tamoxifen therapy continuously for five or more years has contributed to longer survivals in these patients. Several recent reports of possible association between tamoxifen tr...

PURPOSE To evaluate the prognostic value of vascular endothelial growth factor (VEGF)-D and VEGF receptor (VEGFR)-3 in endometrial carcinoma. EXPERIMENTAL DESIGN We assessed the levels of immunoreactivity for VEGF-D and VEGFR-3 in 71 endometrial carcinomas, 14 complex atypical endometrial hyperplasias, and 16 normal endometria by immunohistochemistry. RESULTS VEGF-D was stained in both tumo...

Despite the well-established role of hypoxia in cancer biology, the literature on its effects on endometrial cancer is scarce; it mainly refers to experimental settings rather than patient-derived results. Herein, an overview of the hypoxia inducible factor 1α (HIF-1α) biology, focusing on endometrial cancer, is presented. The molecular mechanisms possibly involved in endometrial cancer progres...

OBJECTIVE To determine the relative frequencies of gynaecological cancers in Ghana, age and parity distribution, stage of disease at presentation and the influence of age and parity on stage at presentation. DESIGN Retrospective observational study. SETTING Korle Bu Teaching Hospital, Accra, Ghana. SUBJECTS Cases of gynaecological cancers seen in a fifty two month period. RESULTS Cervic...

“Vanishing carcinoma” phenomenon has previously reported and accepted on prostate cancer cases as a distinct clinicopathological entity in uro-pathology. However, although it may be seen in cervical and endometrial carcinoma, it has not been evaluated by extensively in gynecology literature. This review has evaluated the ‘’vanishing endometrial carcinoma’’ phenomenon through observing three sim...

Hematometra in a postmenopausal woman is a rare condition and the possible association of endometrial and cervical carcinoma should be excluded for such cases. We report the case of a 66-year-old multiparous postmenopausal woman who presented as an asymptomatical hematometra mimicking endometrial carcinoma. In this case, hematometra was demonstrated by sonography and well defined by computed to...